X-linked Retinoschisis
1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Beacon TherapeuticsMA - Cambridge
2 programs1
rAAV2tYF-CB-hRS1Phase 1/21 trial
Dorzolamide 2% TID or brinzolamide 1% TIDN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Beacon TherapeuticsrAAV2tYF-CB-hRS1
Beacon TherapeuticsDorzolamide 2% TID or brinzolamide 1% TID
Clinical Trials (2)
Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
Start: May 2015Est. completion: May 2023
Phase 1/2Completed
Clinical Evaluation of Patients With X-linked Retinoschisis
Start: Nov 2012Est. completion: Oct 2016
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space